Alternatively, trends observed in the functioning of the intestinal barrier in patients with favorable and unfavorable clinical outcomes of anti-PD-1 therapy may reflect the overall immune activation and the ability of the patient’s immune system to fight cancer. Here, PDCD1 is linked to cancer.